title: Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy.
abstract: BACKGROUND
  Globoid-cell leukodystrophy is caused by a deficiency of galactocerebrosidase, which results in progressive central nervous system deterioration. We investigated whether allogeneic hematopoietic stem-cell transplantation can provide a source of leukocyte galactocerebrosidase and thereby prevent the decline of central nervous system function in patients with the disease.
  
  
  METHODS
  Five children with globoid-cell leukodystrophy (one with the infantile type and four with late-onset disease) were treated with allogeneic hematopoietic stem-cell transplantation. Measurement of leukocyte galactocerebrosidase levels, neurologic examinations, neuropsychological tests, magnetic resonance imaging of the central nervous system, cerebrospinal fluid protein assays, and neurophysiologic measurements were performed before and after transplantation, with follow-up ranging from one to nine years.
  
  
  RESULTS
  Engraftment of donor-derived hematopoietic cells occurred in all patients and was followed by restoration of normal leukocyte galactocerebrosidase levels. In the four patients with late-onset disease, the central nervous system deterioration was reversed, and in the patient with the infantile form of the disease, signs and symptoms have not appeared. Magnetic resonance imaging showed a decrease in signal intensity in the three patients with late-onset disease who were assessed both before and after transplantation. Abnormalities in cerebrospinal fluid total protein levels were corrected in three patients with late-onset disease and substantially reduced in the patient with the infantile form.
  
  
  CONCLUSIONS
  Central nervous system manifestations of globoid-cell leukodystrophy can be reversed by allogeneic hematopoietic stem-cell transplantation.
authors.affiliation: Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, USA.
authors.forename: W
authors.initials: W
authors.lastname: Krivit
authors.forename: E G
authors.initials: EG
authors.lastname: Shapiro
authors.forename: C
authors.initials: C
authors.lastname: Peters
authors.forename: J E
authors.initials: JE
authors.lastname: Wagner
authors.forename: G
authors.initials: G
authors.lastname: Cornu
authors.forename: J
authors.initials: J
authors.lastname: Kurtzberg
authors.forename: D A
authors.initials: DA
authors.lastname: Wenger
authors.forename: E H
authors.initials: EH
authors.lastname: Kolodny
authors.forename: M T
authors.initials: MT
authors.lastname: Vanier
authors.forename: D J
authors.initials: DJ
authors.lastname: Loes
authors.forename: K
authors.initials: K
authors.lastname: Dusenbery
authors.forename: L A
authors.initials: LA
authors.lastname: Lockman
mesh_terms: D002493:Central Nervous System Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D005260:Female; D005698:Galactosylceramidase / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007962:Leukocytes / Q000201:enzymology; D007965:Leukodystrophy, Globoid Cell / Q000150:complications / Q000628:therapy*; D008297:Male; D014184:Transplantation, Homologous
chemical_list: D002556:Cerebrospinal Fluid Proteins; D005698:Galactosylceramidase